Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficiency of ET019003-T Cells in R/R CD19+ B-Cell Malignancies
NCT04014894Phase 1Unknown
- Start
- Jun 2019
- Primary completion
- Jul 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ET019003-T in B cell acute lymphoblastic leukemia (B-ALL) and B cell lymphoma. Primary endpoint: Incidence of Treatment-related Adverse Events at 3 years. Status: unknown.
02
Drugs
ET019003-T
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B cell lymphoma
Beyond the preview
Go deeper on NCT04014894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04014894.